Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk.

Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.

The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.

Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.

Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.

Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.

Mamas Mamas talks to Tesfaye Telila about the landscape of acute coronary care in Ethiopa, where just a few dozen cardiologists contend with a population of 120 million people.

Should we stop anticoagulation therapy before TAVI in patients with aortic stenosis? Dirk-Jan van Ginkel and C. Michael Gibson discuss.

Vijay Kunadian talks to C. Michael Gibson about using an invasive or conservative strategy for older patients with NSTEMI.

Troels Yndigegn, Sripal Bangalore, and Mamas Mamas discuss whether beta-blockers still benefit patients with acute MI and preserved ejection fraction.